When standard treatments fail, patients facing life-threatening conditions often turn to experimental therapies still under investigation. Early access programs—including compassionate use, an expanded access program, and right-to-try pathways—offer hope by providing investigational treatments outside clinical trials. Yet these programs exist at the intersection of profound ethical tensions that challenge our most fundamental values about medical...
